Shares of Teradata Corp (NYSE:TDC) rose sharply in pre-market trading after the company reported better-than-expected third-quarter financial results and raised its FY25 EPS guidance above estimates. Also, the company issued fourth-quarter EPS guidance above estimates.
Teradata reported quarterly earnings of 72 cents per share which beat the analyst consensus estimate of 54 cents per share. The company reported quarterly sales of $416.000 million which beat the analyst consensus estimate of $406.228 million.
Teradata shares jumped 14.6% to $23.73 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
Gainers
- SMX (Security Matters) Public Limited Company (NASDAQ:SMX) gained 70% to $2.50 in pre-market trading after SMX and CARTIF entered into non-binding LOI to integrate SMX’s end-to-end tracing platform into CARTIF’s portfolio and Industry 5.0 projects
- Nuvve Holding Corp. (NASDAQ:NVVE) rose 41.3% to $0.2969 in pre-market trading. Nuvve Holding will provide third quarter update on Thursday, Nov. 13.
- Babcock & Wilcox Enterprises, Inc (NYSE:BW) surged 29.1% to $4.83 in pre-market trading. B&W released four announcements on Tuesday: a $1.5 billion AI data center contract with Applied Digital Corp. (NASDAQ:APLD), third-quarter earnings results, the $29 million sale of the Allen-Sherman-Hoff business, and plans to redeem all remaining February 2026 bonds.
- Entravision Communications Corporation (NYSE:EVC) surged 28.8% to $2.55 in pre-market trading after the company reported a year-over-year increase in third-quarter financial results.
- DirectBooking Technology Co., Ltd. (NASDAQ:ZDAI) gained 28.8% to $0.5829 in pre-market trading.
- Digital Turbine, Inc. (NASDAQ:APPS) gained 26.2% to $7.47 in pre-market trading after the company reported better-than-expected second-quarter financial results and raised its FY26 sales guidance above estimates.
- Kennedy-Wilson Holdings, Inc. (NYSE:KW) surged 23.2% to $9.20 in pre-market trading after CEO William McMorrow and Fairfax Financial submitted a proposal to acquire the company for $10.25 per share in cash.
- Rigel Pharmaceuticals Inc (NASDAQ:RIGL) gained 23.2% to $35.05 in pre-market trading after the company reported better-than-expected third-quarter financial results and raised its FY25 sales guidance above estimates.
- Lumentum Holdings Inc (NASDAQ:LITE) rose 13.5% to $214.00 in pre-market trading after the company reported better-than-expected first-quarter financial results and issued second-quarter guidance above estimates.
Losers
- Biohaven Ltd (NYSE:BHVN) tumbled 46.2% to $7.51 in pre-market trading. Biohaven received FDA Complete Response Letter for VYGLXIA following positive real-world evidence showing 50–70% slowing of spinocerebellar ataxia disease progression.
- Trex Company Inc (NYSE:TREX) declined 31.9% to $32.02 in pre-market trading after the company reported worse-than-expected third-quarter financial results and issued fourth-quarter sales guidance below estimates. Also, the company cut its FY25 sales guidance below estimates.
- Soleno Therapeutics Inc (NASDAQ:SLNO) fell 22.2% to $49.65 in pre-market trading following third-quarter results.
- Axon Enterprise Inc (NASDAQ:AXON) fell 19.6% to $567.50 in pre-market trading after the company reported mixed third-quarter financial results. The company signed an agreement to acquire Carbyne.
- Akari Therapeutics PLC (NASDAQ:AKTX) shares dipped 19.2% to $0.66 in pre-market trading after gaining 13% on Tuesday.
- Pinterest Inc (NYSE:PINS) dipped 18.8% to $26.69 in pre-market trading after the company posted downbeat earnings for the third quarter.
- SSR Mining Inc (NASDAQ:SSRM) fell 17.5% to $17.90 in pre-market trading after posting third-quarter results.
- Uniqure NV (NASDAQ:QURE) fell 15.8% to $25.61 in pre-market trading after gaining 13% on Monday.
- Clover Health Investments Corp (NASDAQ:CLOV) fell 15.5% to $2.97 in pre-market trading after the company reported mixed third-quarter financial results.
- Uniqure NV (NASDAQ:QURE) dipped 11.6% to $30.30 in pre-market trading. The U.S. Food and Drug Administration (FDA) on Monday provided feedback to uniQure regarding its investigational gene therapy for Huntington’s disease.
Now Read This:
Photo via Shutterstock
